We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells advises Jazz Pharmaceuticals

25 May 2016

Hogan Lovells advised the biopharmaceuticals group Jazz Pharmaceuticals in relation to the acquisition by one of its subsidiaries of Alizé Pharma II, a subsidiary of the Alizé Pharma Group.

The cost of the transaction is estimated at EUR 18 million including EUR 8 million as an initial payment and supplementary payments of a total amount of EUR 10 million, subject to regulatory milestones being met.

The Hogan Lovells team advising Jazz pharmaceuticals was led in Paris by Jean-Marc Franceschi (Partner) assisted by Mathieu Frick and Andrea Segura (Associates) for corporate aspects and by Mikael Salmela (Partner) for regulatory aspects and commercial contracts.

Jones Day advised Alizé Pharma, a group operating in the biotechnology sector.

PRESS CONTACT

Eléonore Fleury

+33 1 53 67 18 41

eleonore.fleury@hoganlovells.com

 
Loading data